What Декарис Treats: Main Uses and Benefits

This medication is commonly used as an anti-parasitic agent for conditions such as Ascariasis (roundworm infection) and certain Hookworm infections, and is used for targeted management of infections caused by susceptible parasitic worms (nematodes) in the gastrointestinal tract. This primary therapeutic application is typically utilized when short-term symptomatic assistance is needed and generally may assist with the elimination of the parasite load, helping with the management of the underlying infection and contributing to easing the overall symptom load.

Beyond its primary role, the drug is considered relevant in clinical contexts where supportive modulation of the immune system is appropriate. It is used in addressing situations that involve compromised immune capacity, which is relevant in cases involving certain distressing symptoms associated with chronic infectious states, and in the adjuvant therapy for specific serious underlying conditions. This application supports the maintenance of protective immune responses, assisting the body in managing concurrent or underlying conditions and contributing to improved comfort during symptomatic periods.

“The drug is relevant in contexts involving targeted parasitic clearance and supportive immune modulation.”

Quick Fact: Key Focus on Systemic Imbalance

The medication is commonly used to help manage symptoms related to systemic imbalance relevant in conditions characterized by symptomatic patterns stemming from either parasitic presence or compromised immune responses.

Regulatory References

1. European Medicines Agency overview

Official Eligibility Profile

Decaris (Levamisole) is a medicine with a strictly defined eligibility profile based on patient health status and physiological state, as outlined in authoritative regulatory documents.

Contraindicated Populations (Must NOT Use)	Populations Requiring Special Caution
Known hypersensitivity to the drug or components	Hepatic impairment (Liver disease)
Pre-existing blood disorders (e.g., leukopenia)	Epilepsy or history of convulsions
Severe renal impairment (Kidney failure)	Sjögren's syndrome
Pregnancy and Lactation (Breastfeeding)	Rheumatoid arthritis (listed in some sources)

Age Eligibility: The medicine is used in both Adults and Children. However, some regulatory sources note that studies have primarily involved adult patients, though the standard therapeutic dose is applied to both age groups for treatment.

Eligibility Summary: The medicine is strictly contraindicated in patients with a history of serious blood or kidney conditions, or known allergy to the drug. Use in pregnant and breastfeeding women is also prohibited or not recommended due to documented risk or insufficient safety data. Conditional use under medical supervision is mandated for those with certain chronic conditions like liver disease and epilepsy.

Levamisole, the active substance in Decaris, has the potential to interact with several other medications and substances. It is essential to inform a healthcare professional about all medicines, over-the-counter drugs, vitamins, and herbal supplements currently being taken to prevent adverse effects.

Potential Drug-Drug Interactions

Interacting Medicine Category	Specific Examples (where available)	Potential Effect
Anticoagulants	Warfarin	Levamisole may increase the effects of anticoagulants, leading to an increased risk of bleeding. Close monitoring of blood clotting parameters (INR) is necessary.
Anticonvulsants	Phenytoin	Levamisole may raise the concentration of anticonvulsants in the blood, potentially leading to increased toxicity and side effects.
Chemotherapy Agents	Fluorouracil (5-FU)	When used in combination therapy (for non-anthelmintic uses), levamisole may affect the metabolism of other chemotherapy drugs.
Other Anthelmintics	Albendazole, Ivermectin	Levamisole may affect the way the body absorbs or processes other anti-worm medications, potentially altering the efficacy or side-effect profile of these drugs.

Interaction with Alcohol and Food

Consumption of alcohol while taking Decaris is strongly discouraged. This combination can result in a disulfiram-like reaction, which includes unpleasant symptoms such as severe headache, flushing, nausea, vomiting, dizziness, and abdominal discomfort. Decaris can typically be taken with or without food.

Mechanism of Rapid Parasite Paralysis

The drug's primary action is exerted through cholinergic agonism, where the active ingredient, Levamisole, binds to and overstimulates specific nicotinic acetylcholine receptors (nAChRs) on the somatic muscle cells of susceptible parasitic worms. This molecular interaction causes immediate and sustained depolarization of the muscle membrane, leading directly to a state of spastic paralysis. The resulting physiological event is the worm's complete loss of mobility and anchoring capacity, which facilitates its passive displacement by intestinal peristalsis.

️ Modulation of Host Cellular Immunity

Levamisole possesses a secondary, distinct mechanism focused on immunomodulation. This process involves the drug interacting with key components of the host's defense system, specifically T-lymphocytes, macrophages, and neutrophils. It acts to restore and potentiate the function of these cells when their activity is depressed, enhancing processes such as phagocytosis and T-cell proliferation. The physiological consequence is a targeted adjustment of the cellular immune response, involving modulation toward immune homeostasis.

Pharmacological Specificity and Limitations

The drug’s precise action relies on its purified L-isomer form for maximal potency. However, the anthelmintic mechanism is constrained by the biological status of its target; its effectiveness is reduced or eliminated if parasitic strains develop resistance. This resistance is a purely mechanistic limitation, resulting from genetic changes that alter the structure or density of the target nAChRs, preventing the crucial paralyzing agonist action.

Administration Route and Dosing Regimens

The administration of Декарис (Levamisole) is prescribed for oral use via a tablet formulation. The standard adult regimen for anthelmintic treatment is based on a single oral dose of 150 mg, which represents the typical short-term course duration for these parasitic conditions. It is a procedural requirement that the labeled dose, including the 150 mg maximum single dose, is calculated and expressed in terms of the Levamisole free base, not the hydrochloride salt. The usage structure also includes a distinct cyclic pattern for immune-supportive purposes, involving a structured 50 mg dose taken three times daily (every 8 hours) for three consecutive days, followed by a 2-week interval.

---

Population and Time-Based Instructions

Administration rules for specific populations are established to ensure accurate intake. Pediatric dosing is weight-adjusted, requiring 2.5 mg/kg to 3 mg/kg of body weight, administered as a single oral dose for specific parasitic infections. The medication is generally administered without explicit requirements regarding food intake. For any multi-day regimen, the instruction for a missed dose is to skip the missed dose and resume the next scheduled administration, maintaining the defined interval. Furthermore, the medicine should be used with caution in individuals with renal impairment.

Research Evidence Overview of Studies for Декарис

---

Evidence for Use in Parasitic Infections (Anthelmintic Action)

A substantial volume of formal research for Levamisole has focused on its evaluation in parasitic infections. This evidence base consists of numerous short-term randomized controlled trials (RCTs) and is synthesized in various systematic reviews and meta-analyses. Studies primarily focus on populations of adults and children living in areas where certain parasitic worms are common. Researchers examined outcomes related to systemic or functional imbalance, such as measuring the change in parasite load and monitoring the elimination of parasite eggs (cure rate).

The research so far indicates that measurements relating to the elimination of parasite eggs and changes in the egg burden for certain hookworms were described across many trials conducted over time. These findings describe patterns observed in the studies that help contextualize the outcomes related to systemic or functional imbalance. Long-term outcomes are not well characterized, and there is an ongoing scientific need to monitor for potential shifts in parasite patterns related to anthelmintic resistance.

---

Evidence for Use in Certain Immune-Related Conditions (Immunomodulatory Action)

Levamisole was studied for a supportive role in modulating the immune system, particularly in treating conditions characterized by fluctuating or episodic manifestations, such as frequently relapsing or steroid-dependent Nephrotic Syndrome in pediatric populations. The evidence available includes RCTs that aimed to evaluate strategies related to patient corticosteroid requirements. Studies monitored outcomes related to functional imbalance, specifically focusing on the time until the first relapse (episode of heightened symptom activity) and the overall frequency of relapses over defined time intervals.

Findings describe patterns observed in the studies where the time between relapse episodes was observed in some studies to be longer in the groups receiving Levamisole compared to control groups over monitoring periods ranging from six to twelve months. However, the certainty for some findings remains low due to methodological heterogeneity, and research remains insufficient for the drug’s potential use in other immune-related conditions.

---

Research Gaps and Uncertainties

The evidence landscape highlights several areas where knowledge is still developing. Although the core anti-worm action was studied for short-term outcomes, the comparative evidence is lacking regarding its performance against many contemporary anti-worm medications. The key limitations cited in scientific literature include modest sample sizes and variability across studies in the way the condition and outcomes were defined.

Key Studies & References

1. PRAC starts safety review of levamisole, medicine used to treat parasitic worm infections (EMA)

Common questions about Декарис (FAQ)

Q: What is Декарис (Decaris)?

A: Декарис (Decaris) is a brand name for the medicine levamisole, which belongs to a class of medicines called anthelmintics. It is used to treat infections caused by various parasitic worms, such as Ascaris lumbricoides (roundworm) and hookworms (Necator americanus and Ancylostoma duodenale).

---

Q: How does levamisole work to treat worm infections?

A: Levamisole works by selectively targeting the neuromuscular system of the parasitic worms. It acts as a nicotinic acetylcholine receptor agonist, which causes continuous stimulation of the worm's muscles. This leads to muscle contraction, paralysis, and eventual expulsion of the worms from the body.

---

Q: What are the common side effects of levamisole?

A: Common side effects may include:

• Abdominal discomfort or pain
• Nausea and vomiting
• Headache
• Dizziness

Some users have also reported a decreased white blood cell count (lymphocytopenia). If you experience any severe or unusual symptoms, you should contact your doctor.

---

Q: Is it safe to use levamisole during pregnancy or while breastfeeding?

A: Pregnancy: Levamisole may be unsafe for use during pregnancy, as animal studies have shown potential harmful effects on the developing baby. You should consult a healthcare professional, as they will weigh the potential benefits against any risks before prescribing it. Birth control measures may be advised to prevent pregnancy during treatment.

Breastfeeding: The use of levamisole while breastfeeding is generally considered safe if prescribed by a doctor. Limited human data suggests the drug does not represent a significant risk to the baby.

---

Q: Can levamisole affect my ability to drive or operate machinery?

A: Levamisole may cause side effects such as drowsiness, dizziness, or blurred vision, which can decrease alertness. It is generally advised not to drive or operate heavy machinery if you experience these symptoms.

---

Q: Are there any serious safety concerns associated with levamisole?

A: Yes, there have been concerns and safety reviews regarding a risk of leukoencephalopathy with levamisole, a potentially serious condition that damages the white matter of the brain. This condition can be life-threatening and may lead to neurological symptoms, including confusion, weakness, or impaired speech and vision. Additionally, the drug has been associated with an increased risk of serious infections due to a potential decrease in white blood cell count. Your doctor may monitor your blood counts and liver function before and during treatment.

How to Store and Dispose of Декарис (Levamisole)

Official regulatory guidelines define specific conditions to maintain the stability and safety of Decaris (Levamisole) tablets.

Storage Conditions

Condition	Requirement
Temperature	Store in a cool place; do not store above 25 C and keep from freezing.
Protection	Store in a dry place, protected from light and direct sunlight.
Container	Keep in the tightly closed original, properly labelled container.
Child Safety	Must be stored locked up and kept out of the reach of children.

The product maintains a 2-year shelf life when stored according to these mandatory conditions.

Disposal Requirements

Do not keep outdated medicine. Dispose of unused product and its container according to national waste disposal regulations, typically at an approved waste disposal plant. It is prohibited to contaminate surface waters or ditches with the product.